合計 50 件の最近のインサイダー取引記録が記録されています Immunome, Inc. (IMNM), 内訳は 39 件の買い および 7 件の売り. インサイダー買い総額は $51.5M インサイダー売り総額は $2.12M.
最近活動のある主要インサイダーには Higgins Jack, Rosett Max, Siegall Clay B. インサイダー取引記録は、経営陣が株式の評価と将来の見通しをどう見ているかについての洞察を提供します.
インサイダー取引記録 — IMNM
| 日付 |
氏名 |
役職 |
取引種別 |
株数 |
平均価格 |
価値 |
保有株数 |
| 2026-04-02 |
Higgins Jack |
Chief Scientific Officer |
情報に基づく売り |
9,438 |
$21.64 |
$204.24K |
22,000 |
| 2026-04-02 |
Rosett Max |
Chief Financial Officer |
オプション行使（売却） |
39,713 |
$1.35 |
$53.61K |
- |
| 2026-03-30 |
Higgins Jack |
Chief Scientific Officer |
贈与（送付） |
6,291 |
- |
- |
31,438 |
| 2026-03-27 |
Siegall Clay B |
President and CEO |
情報に基づく買い |
25,450 |
$19.67 |
$500.6K |
690,704 |
| 2026-03-23 |
Wagenheim Philip |
Director |
情報に基づく売り |
28,200 |
$20.65 |
$582.33K |
341,147 |
| 2026-03-20 |
Wagenheim Philip |
Director |
情報に基づく売り |
36,800 |
$20.47 |
$753.3K |
369,347 |
| 2026-03-11 |
Bienaime Jean Jacques |
Director |
情報に基づく買い |
1,000 |
$21.55 |
$21.55K |
38,415 |
| 2026-03-10 |
Bienaime Jean Jacques |
Director |
情報に基づく買い |
1,000 |
$22.12 |
$22.12K |
37,415 |
| 2025-12-30 |
Siegall Clay B |
President and CEO |
情報に基づく買い |
4,729 |
$21.15 |
$100.02K |
665,254 |
| 2025-12-22 |
Barchas Isaac |
Director |
情報に基づく売り |
11,251 |
$22.34 |
$251.35K |
2,031,181 |
| 2025-12-19 |
Siegall Clay B |
President and CEO |
贈与（送付） |
200,000 |
- |
- |
660,525 |
| 2025-12-19 |
Higgins Jack |
Chief Scientific Officer |
贈与（受領） |
1,000 |
- |
- |
1,000 |
| 2025-12-19 |
Tsai Philip |
Chief Technical Officer |
情報に基づく買い |
10,000 |
$20.49 |
$204.9K |
43,300 |
| 2025-12-18 |
Siegall Clay B |
President and CEO |
情報に基づく買い |
46,511 |
$21.50 |
$999.99K |
853,247 |
| 2025-09-10 |
Higgins Jack |
Chief Scientific Officer |
オプション行使 |
22,000 |
$1.35 |
$29.7K |
40,729 |
| 2025-07-29 |
Siegall Clay B |
President and CEO |
RSU 付与（制限付株式） |
800,000 |
$10.60 |
$8.48M |
800,000 |
| 2025-07-29 |
Stoneman Sandra G. |
Chief Legal Officer & Gc |
RSU 付与（制限付株式） |
190,000 |
$10.60 |
$2.01M |
190,000 |
| 2025-07-29 |
Horn Kinney |
Chief Business Officer |
RSU 付与（制限付株式） |
161,000 |
$10.60 |
$1.71M |
161,000 |
| 2025-07-29 |
Higgins Jack |
Chief Scientific Officer |
RSU 付与（制限付株式） |
196,000 |
$10.60 |
$2.08M |
196,000 |
| 2025-07-29 |
Rosett Max |
Chief Financial Officer |
RSU 付与（制限付株式） |
207,000 |
$10.60 |
$2.19M |
207,000 |
| 2025-07-29 |
Lechleider Robert |
Chief Medical Officer |
RSU 付与（制限付株式） |
242,000 |
$10.60 |
$2.57M |
242,000 |
| 2025-07-29 |
Tsai Philip |
Chief Technical Officer |
RSU 付与（制限付株式） |
190,000 |
$10.60 |
$2.01M |
190,000 |
| 2025-06-10 |
Bienaime Jean Jacques |
Director |
RSU 付与（制限付株式） |
18,864 |
$9.57 |
$180.53K |
18,864 |
| 2025-06-10 |
Schafer Carol |
Director |
RSU 付与（制限付株式） |
18,864 |
$9.57 |
$180.53K |
18,864 |
| 2025-06-10 |
Wagenheim Philip |
Director |
RSU 付与（制限付株式） |
18,864 |
$9.57 |
$180.53K |
18,864 |
| 2025-06-10 |
Barchas Isaac |
Director |
RSU 付与（制限付株式） |
18,864 |
$9.57 |
$180.53K |
18,864 |
| 2025-06-10 |
Swain Sandra M |
Director |
RSU 付与（制限付株式） |
18,864 |
$9.57 |
$180.53K |
18,864 |
| 2025-06-10 |
Boylan James P |
Director |
RSU 付与（制限付株式） |
18,864 |
$9.57 |
$180.53K |
18,864 |
| 2025-06-03 |
Bienaime Jean Jacques |
Director |
情報に基づく買い |
5,000 |
$9.38 |
$46.9K |
36,415 |
| 2025-03-27 |
Higgins Jack |
Chief Scientific Officer |
オプション行使 |
5,200 |
$1.35 |
$7.02K |
18,729 |
| 2025-03-26 |
Siegall Clay B |
President and CEO |
情報に基づく買い |
137,100 |
$7.29 |
$999.46K |
806,736 |
| 2025-03-25 |
Bienaime Jean Jacques |
Director |
情報に基づく買い |
7,800 |
$7.78 |
$60.68K |
31,415 |
| 2025-03-24 |
Bienaime Jean Jacques |
Director |
情報に基づく買い |
7,000 |
$8.21 |
$57.47K |
23,615 |
| 2025-03-24 |
Tsai Philip |
Chief Technology Officer |
情報に基づく買い |
12,300 |
$8.42 |
$103.57K |
33,300 |
| 2025-01-31 |
Siegall Clay B |
President and CEO |
情報に基づく買い |
150,000 |
$7.75 |
$1.16M |
669,636 |
| 2024-11-22 |
Siegall Clay B |
President and CEO |
情報に基づく買い |
33,943 |
$9.78 |
$331.92K |
519,636 |
| 2024-11-21 |
Siegall Clay B |
President and CEO |
情報に基づく買い |
66,057 |
$9.54 |
$630.26K |
485,693 |
| 2024-11-21 |
Lechleider Robert |
Chief Medical Officer |
情報に基づく買い |
15,805 |
$9.48 |
$149.8K |
15,805 |
| 2024-11-21 |
Tsai Philip |
Chief Technology Officer |
情報に基づく買い |
21,000 |
$9.43 |
$198.03K |
21,000 |
| 2024-09-19 |
Rosett Max |
Chief Financial Officer |
情報に基づく売り |
14,380 |
$16.01 |
$230.22K |
47,476 |
| 2024-08-19 |
Higgins Jack |
Chief Scientific Officer |
贈与（送付） |
2,471 |
- |
- |
13,529 |
| 2024-08-16 |
Bienaime Jean Jacques |
Director |
情報に基づく買い |
7,000 |
$13.94 |
$97.61K |
16,615 |
| 2024-08-15 |
Higgins Jack |
Chief Scientific Officer |
情報に基づく売り |
3,524 |
$13.93 |
$49.07K |
16,000 |
| 2024-08-09 |
Siegall Clay B |
President and CEO |
RSU 付与（制限付株式） |
800,000 |
$12.92 |
$10.34M |
800,000 |
| 2024-08-09 |
Stoneman Sandra G. |
Chief Legal Officer & Gc |
RSU 付与（制限付株式） |
210,000 |
$12.92 |
$2.71M |
210,000 |
| 2024-08-09 |
Horn Kinney |
Chief Business Officer |
RSU 付与（制限付株式） |
130,000 |
$12.92 |
$1.68M |
130,000 |
| 2024-08-09 |
Turner Bruce |
Chief Strategy Officer |
RSU 付与（制限付株式） |
110,000 |
$12.92 |
$1.42M |
110,000 |
| 2024-08-09 |
Higgins Jack |
Chief Scientific Officer |
RSU 付与（制限付株式） |
190,000 |
$12.92 |
$2.45M |
190,000 |
| 2024-08-09 |
Rosett Max |
EVP, Operations & CFO |
RSU 付与（制限付株式） |
190,000 |
$12.92 |
$2.45M |
190,000 |
| 2024-08-09 |
Lechleider Robert |
Chief Medical Officer |
RSU 付与（制限付株式） |
200,000 |
$12.92 |
$2.58M |
200,000 |
■ 情報付き — 公開市場取引（最も重要）
■ 情報なし（買い） — 報酬・オプション行使・転換
■ 情報なし（売り） — 源泉徴収・付与売却
■ 中立 — 贈与・信託・失効
